Actively Recruiting

Phase Not Applicable
Age: 18Years +
All Genders
ID07027202

Early Preventive Left Ventricle Unloading After VA-ECMO for Refractory Cardiogenic Shock

Led by Assistance Publique - Hôpitaux de Paris · Updated on 2026-04-13

298

Participants Needed

12

Research Sites

4 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

Researchers are evaluating the impact of early preventive left ventricle unloading using an intra-aortic balloon pump (IABP) in patients receiving venoarterial extracorporeal membrane oxygenation (VA-ECMO) for severe cardiogenic shock. Cardiogenic shock often results from conditions like acute myocardial infarction or end-stage heart failure, and VA-ECMO is used to support heart function. However, VA-ECMO can increase left ventricular afterload, potentially worsening outcomes by causing complications such as pulmonary congestion and delaying heart recovery or transplantation. Previous studies have produced mixed results, highlighting the need for a well-powered trial to assess early unloading benefits compared to conventional care.

CONDITIONS

Brief Title

Early Preventive Left Ventricle Unloading After VA-ECMO for Refractory Cardiogenic Shock

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Patient on peripheral femoro-femoral VA ECMO for severe cardiogenic shock for 24 hours or less
  • Initiation of left ventricle unloading possible within 12 hours after randomization
  • Consent obtained from a close relative or surrogate, or emergency consent with later patient consent when possible
  • Registered with social security (AME excluded)
Not Eligible

You will not qualify if you...

  • Age under 18 years
  • Pregnancy
  • VA-ECMO started more than 24 hours before
  • Overt pulmonary edema requiring urgent unloading despite optimized management
  • ECMO for massive pulmonary embolism or primary right ventricular failure
  • ECMO after heart transplant
  • ECMO after left ventricular assist device surgery
  • Resuscitation longer than 30 minutes before ECMO unless fully conscious at randomization
  • ECMO for refractory cardiac arrest (E-CPR)
  • Grade 3-4 aortic regurgitation
  • Mechanical complications of acute myocardial infarction (massive mitral regurgitation, pericardial drainage, septal ventricular defect)
  • Patient moribund on day of randomization
  • Cerebral deficit with fixed dilated pupils or irreversible neurological pathology
  • Severe concomitant disease with life expectancy under 1 year
  • Existing durable ventricular assist device, IABP, or other temporary mechanical support before enrollment
  • Severe peripheral artery disease or prior aortic/ilio-femoral surgery preventing IABP or Impella insertion

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Your Study Journey

Screening

Duration - 2 to 4 weeks

Participants are screened for eligibility to participate in the trial.

Participants must be on peripheral femoro-femoral VA ECMO for severe cardiogenic shock for 24 hours or less and meet other criteria before enrollment.

Treatment

Duration - Up to 30 days post-randomization

Participants receive early left ventricle unloading with an intra-aortic balloon pump inserted as soon as possible, within 12 hours post-randomization. Hemodynamic monitoring with a pulmonary artery catheter and daily Doppler echocardiography are performed. Escalations to additional unloading procedures may occur if needed.

Continuous monitoring with daily Doppler echocardiography and ongoing clinical assessments during hospitalization.

Follow-up

Duration - Up to 60 days post-randomization

Participants are monitored for outcomes including mortality, complications related to unloading devices, duration of mechanical support, and hospital stay up to 60 days after randomization.

Periodic assessments up to Day 60 to track recovery and complications.

Trial Site Locations

Total: 12 locations

1

CHU Clermont-Ferrand - Site Gabriel Montpied

Clermont-Ferrand, France, 63000

Not Yet Recruiting

2

Henri Mondor

Créteil, France, 94000

Not Yet Recruiting

3

Hôpital Cardiologique

Lille, France, 59000

Not Yet Recruiting

4

APHP - hôpital Pitié-Salpêtrière

Paris, France, 75013

Actively Recruiting

5

APHP - hôpital Pitié-Salpêtrière

Paris, France, 75013

Not Yet Recruiting

6

APHP - hôpital Pitié-Salpêtrière

Paris, France, 75013

Not Yet Recruiting

7

Hôpital Européen Georges Pompidou

Paris, France, 75015

Not Yet Recruiting

8

Hôpital du Pontchaillou

Rennes, France, 35033

Not Yet Recruiting

9

Nouvel Hôpital Civil

Strasbourg, France, 67000

Not Yet Recruiting

10

Nouvel hôpital civil

Strasbourg, France, 67000

Not Yet Recruiting

11

Hôpital Rangueil

Toulouse, France, 31059

Not Yet Recruiting

12

CHRU Nancy - hôpitaux de brabois

Vandœuvre-lès-Nancy, France, 54500

Not Yet Recruiting

Loading map...

Research Team

A

Alain COMBES, MD

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

OTHER

Number of Arms

2

Similar Trials

FEMART-1 Pilot Study Evaluating Prehospital Femoral Arterial...

Sudden Cardiac Arrest

Actively Recruiting

1 location

Prognosis of Patients With Mixed Cardiogenic-Vasoplegic Shoc...

Cardiogenic Shock Acute

Actively Recruiting

1 location

Frequently Asked Questions

Have more questions? Get in touch with our team for quick support

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here